Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation

Area of Science:

• Hematology
• Pulmonology
• Transplantation Medicine

Background:

• Pulmonary complications are frequent after hematopoietic cell transplantation (HCT), significantly impacting patient morbidity and mortality.
• Diffuse alveolar hemorrhage (DAH) is a serious non-infectious complication affecting up to 5% of post-HCT patients, with historically high mortality rates (60-100%).

Purpose of the Study:

• To review the pathogenesis of diffuse alveolar hemorrhage (DAH) in hematopoietic cell transplantation (HCT) recipients.
• To discuss current and potential treatment strategies for DAH post-HCT.

Main Methods:

• Review of existing literature on diffuse alveolar hemorrhage (DAH) following hematopoietic cell transplantation (HCT).
• Analysis of clinical presentation, diagnostic methods, and therapeutic interventions for DAH.

Main Results:

• The exact etiology of DAH is not fully understood but involves lung injury from conditioning regimens, irradiation, infections, and comorbidities like graft-versus-host disease.
• Clinical signs include hypoxemia, dyspnea, and diffuse lung opacities; diagnosis is confirmed via bronchoscopy and bronchoalveolar lavage findings.
• Treatment often involves glucocorticoids, with variable efficacy; other agents like antifibrinolytics and factor VIIa have shown mixed results.

Conclusions:

• Diffuse alveolar hemorrhage (DAH) is a critical complication of hematopoietic cell transplantation (HCT) requiring further research into its pathogenesis.
• Optimal treatment strategies for DAH remain to be defined, highlighting the need for standardized therapeutic approaches.